Linarin improves the dyskinesia recovery in Alzheimer's disease zebrafish by inhibiting the acetylcholinesterase activity

Due to complex pathogenesis of Alzheimer's disease (AD), currently there is no effective disease-modifying treatment. Acetylcholinesterase (AChE) has introduced itself as an important target for AD therapy. Linarin as the representative active ingredient of flavonoid glycoside in Flos chrysanth...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2019-04, Vol.222, p.112-116
Main Authors: Pan, Hongye, Zhang, Jinghui, Wang, Yangyang, Cui, Keke, Cao, Yueting, Wang, Longhu, Wu, Yongjiang
Format: Article
Language:English
Subjects:
Acetylcholinesterase
Acetylcholinesterase inhibitor
Aluminum chloride
Alzheimer's disease
Computer simulation
Danio rerio
Donepezil
Dyskinesia
Inhibition
Linarin
Medical treatment
Molecular docking
Neurodegenerative diseases
Pathogenesis
Recovery
Simulation
Zebrafish
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to complex pathogenesis of Alzheimer's disease (AD), currently there is no effective disease-modifying treatment. Acetylcholinesterase (AChE) has introduced itself as an important target for AD therapy. Linarin as the representative active ingredient of flavonoid glycoside in Flos chrysanthemi indici has been found to have anti-acetylcholinesterase effect. The present study intended to explore the potential effect of linarin for treatment of AD. In this study, molecular docking simulation was used to evaluate whether linarin could dock with AChE and decipher the mechanism of linarin as an AChE inhibitor. After molecular docking simulation, AlCl3-induced Alzheimer's disease zebrafish model was established. Effects of linarin on treating AD zebrafish dyskinesia and AChE inhibition were compared with donepezil (DPZ) which was used as a positive control drug. Molecular docking simulation showed that linarin plays a critical role in AChE inhibition by binding AChE active sites. The experiments illustrated that the dyskinesia recovery rate of AD zebrafish could be significantly improved by linarin. The dyskinesia recovery and AChE inhibition rate were 88.0% and 74.5% respectively, while those of DPZ were 79.3% and 43.6%. These findings provide evidences for supporting linarin to be developed into an AD drug by inhibiting the activity of AChE. [Display omitted]
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2019.02.046